Evidence map›Paper›PMID 41532156›Full record

ArticleSmall methods2026

Cardenolide-Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non-small Cell Lung Cancer Cells.

Maja Dorfner, Anika Mifka, Rodrigo Maia de Pádua, Izabella Thaís da Silva, Iara Zanella Guterres, Lorenzo Sana, Gregor Fuhrmann, Jennifer Munkert

Abstract read
In one paragraph

Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maja DorfnerPharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0009-0001-3362-3664
Anika MifkaPharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Rodrigo Maia de PáduaDepartment of Pharmaceutical Products, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0002-9939-6900
Izabella Thaís da SilvaDepartment of Pharmaceutical Sciences, Federal University Santa Catarina, Florianopolis, SC, Brazil.ORCID https://orcid.org/0000-0002-1893-4317
Iara Zanella GuterresDepartment of Pharmaceutical Sciences, Federal University Santa Catarina, Florianopolis, SC, Brazil.ORCID https://orcid.org/0000-0002-1243-3765
Lorenzo SanaPharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Gregor FuhrmannPharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0002-6688-5126
Jennifer MunkertPharmaceutical Biology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.ORCID https://orcid.org/0000-0001-9799-8804

Funding

Bayerisches Hochschulzentrum für LateinamerikaDeutsche Forschungsgemeinschaft 511550821Dr. Hertha and Helmut Schmauser-FoundationFAU Gender and Diversity FundGerman Research Council for financial support of the PharmBio EV facility for our large-scale equipment 511550821H2020 European Research Council 945602Universitätsbund Erlangen-Nürnberg
6 · The paper itself

Abstract

Cancer remains a leading cause of premature mortality worldwide. Targeted drug delivery therapies that selectively attack malignant cells while sparing healthy tissue are essential to minimize side effects and reduce drug dosages. The sodium-potassium ATPase (Na

Indexed as

Carcinoma, Non-Small-Cell LungCardenolidesDoxorubicinExtracellular VesiclesLung NeoplasmsA549 CellsAntineoplastic AgentsCell SurvivalDrug CarriersDrug Delivery SystemsHumansSodium-Potassium-Exchanging ATPaseAntineoplastic AgentsCardenolidesDoxorubicinDrug CarriersSodium-Potassium-Exchanging ATPaseA549 non‐small cell lung cancer (NSCLC) cell linecardenolide derivative 3β‐azido‐3‐deoxydigitoxigeninNa+/K+‐ATPase inhibition assaysurface‐modification by click chemistrytarget drug delivery

Identifiers

PMID41532156
PMCPMC12893248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.